Bio-Techne Corp (TECH) is a Healthcare stock trading at $72.40 (as of 2026-09-18), with a market capitalization of $11.34B and a trailing P/E of 89.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Bio-Techne sells the reagents, antibodies, and cell-culture products that researchers and drug-makers consume daily, alongside diagnostic instruments and tests. Protein Sciences supplies roughly 77% of revenue on recurring reagent sales, while Diagnostics and Spatial Biology is the smaller, instrument-led growth sleeve.
Once a lab installs Bio-Techne's IP-protected reagents (proprietary antibodies, cytokines), it pays a 67-gross-margin refill bill every quarter; the instruments seed the install base, the consumables keep the cash flowing.
| Protein Sciences | $0.2B |
| Diagnostics & Spatial Biology | $0.1B |
Business quality (Mixed): High-margin reagent moat (67% gross) on a ~$1.2B annual run-rate, but revenue just turned negative and the 75.6x multiple prices in a biotech-funded recovery that has not yet appeared.
Valuation: At 76× earnings, TECH trades 341% above the Pharmaceutical Products average (17×).
| Price | $72.40 |
| Market Cap | $11.34B |
| P/E Ratio | 89.1 |
| Price / Book | 5.38 |
| Price / Sales | 9.33 |
| Dividend Yield | 0.4% |
| FCF Yield | 2.3% |
| DCF Value (model) | $14.60 |
| DCF Upside vs Price | -79.8% |
| Revenue (TTM) | $1.22B |
| Net Margin | 15.0% |
| Return on Equity | 6.0% |
| Current Ratio | 4.55 |
| Revenue Growth (YoY) | 1.3% |
| FCF Growth (YoY) | -6.8% |
| Altman Z-Score | 15.84 (safe) |
| Piotroski F-Score | 8/9 (strong) |
| Stock P/E | 89.1 |
| Sector P/E (Healthcare) | 21.5 |
| Industry P/E (Pharmaceutical Products) | 16.0 |
| vs Sector | 315.0% |
| vs Industry | 456.2% |
| Top Institutional Holder | Decagon Asset Management LLP ($39.89B) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 6 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | Kim Kelderman |
| Employees | 3,100 |
| Country | US |
| IPO Date | 1989-02-09 |
Data as of 2026-09-18.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.